Health-related quality of life in subjects with HCV/HIV coinfection: Results from ACTG 5178 study

Journal of Viral Hepatitis

Volumn 19, Issue 11, 2012, Pages 792-800

  Kemmer, N ^a   Hua, L ^b   Andersen, J W ^b   Chung, R T ^c   Butt, A A ^d,e   Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

coinfection; HCV; health related quality of life; HIV; treatment

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DISTRESS SYNDROME; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; COINFECTION; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84867400546     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01609.x     Document Type: Article

References (26)

1. Sherman KE, Soriano V, Chung RT,. Human immunodeficiency virus and liver disease: conference proceedings. Hepatology 2010; 51: 1046-1054.
2. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010; 55: 597-605.
3. Bozzette SA, Hays RD, Berry SH, Kanouse DE, Wu AW,. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 253-265.
4. Coplan PM, Cook JR, Carides GW, et al. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis 2004; 39: 426-433.
5. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54 (Suppl 1): S77-S90.
6. Andresen EM, Malmgren JA, Carter WB, Patrick DL,. Screening for depression in well older adults: evaluation of a short form of the CES-D (center for epidemiologic studies depression scale). Am J Prev Med 1994; 10: 77-84.
7. Kilbourne AM, Justice AC, Rollman BL, et al. Clinical importance of HIV and depressive symptoms among veterans with HIV infection. J Gen Intern Med 2002; 17: 512-520.
8. Fleming CA, Christiansen D, Nunes D, et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004; 38: 572-578.
9. Kanwal F, Gralnek IM, Hays RD, et al. Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample. Am J Gastroenterol 2005; 100: 1984-1994.
10. Thein H, Maruff P, Krahn M, et al. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med 2007; 8: 192-202.
11. Bonkovsky HL, Woolley JM,. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The consensus interferon study group. Hepatology 1999; 29: 264-270.
12. Bonkovsky HL, Woolley JM,. Outcomes research in chronic viral hepatitis C: effects of interferon therapy. Can J Gastroenterol 2000; 14 (Suppl B): 21B-29B.
13. Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kd) [pegasys] improves hr-qol outcomes compared with unmodified interferon alpha-2a [roferon-a]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-349.
14. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681.
15. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
16. Bokemeyer M, Ding XQ, Goldbecker A, et al. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut 2011; 60: 370-377.
17. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851.
18. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808.
19. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005; 19 (Suppl 3): S79-S84.
20. Clifford DB, Evans SR, Yang Y, Gulick RM,. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 2005; 19 (Suppl 3): S64-S71.
21. Arguedas MR, DeLawrence TG, McGuire BM,. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-1626.
22. Kalaitzakis E, Josefsson A, Bjornsson E,. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol 2008; 8: 46.
23. Citro V, Milan G, Tripodi FS, et al. Mental status impairment in patients with west haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol 2007; 42: 79-82.
24. Bjornsson E, Verbaan H, Oksanen A, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol 2009; 44: 878-887.
25. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
26. Snow KK, Bonkovsky HL, Fontana RJ, et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 719-734.